Alkermes, Inc. (NASDAQ: ALKS) today announced that it has developed a
novel, proprietary LinkeRx™ technology platform to enable the creation
of injectable extended-release versions of antipsychotics and other
central nervous system (CNS) therapies. The company’s lead candidate
that leverages this platform, designated as ALKS 9070, is a
once-monthly, injectable, extended-release version of aripiprazole for
the treatment of schizophrenia. Aripiprazole is commercially available
under the name ABILIFY® for the treatment of a number of CNS
disorders.
“Alkermes’ expertise in developing safe and effective long-acting
therapeutics uniquely positions us to develop a once-monthly version of
aripiprazole.”
“We are pleased to build upon our expertise in developing long-acting
platforms and therapies to bring forward a once-monthly version of
aripiprazole, a widely prescribed product with a proven safety and
efficacy profile,” stated Dr. Elliot Ehrich, Chief Medical Officer of
Alkermes. “Multiple studies have shown that long-acting therapies in the
treatment of schizophrenia can lead to improved patient outcomes and
reduced costs. An additional extended-release injectable medication
would provide another valuable option for patients and physicians to
manage this serious, chronic disease.”
Based on encouraging preclinical results, ALKS 9070 is expected to enter
the clinic in the second half of calendar 2010. A number of patent
applications have been submitted to the U.S. Patent and Trademark Office
to protect the LinkeRx technology and ALKS 9070.